



Supplementary Fig. S2.


A




B




C




D




E




F




G



H



I



Supplementary Fig. S2.

(A) Immunoblotting of APC and TDO2 in uncloned MC38 cells, APC-positive clones, and APC-deleted clones of MC38 cells. **(B)** Immunoblots for TDO2 and TCF4 in Caco-2 cell lysates after transfecting with shControl or three individual shTCF4s **(C-E)** Immunoblots for TDO2 and TCF4 in HCT-15, DLD-1, and iKAP cell lysates after transfecting with siControl or three individual siTCF4s. **(F-I)** Immunoblots for TDO2 and β -catenin upon XAV-939 treatment of DLD-1, Caco-2, HCT-15, and iKAP cell lines at indicated doses for 36 hr. At least two independent experiments were performed unless otherwise stated.